Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CannaPharmaRX, Inc. (CPMD)
USD0.00
+0.00 (+0.00%)
CA OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
888 3rd Street SW T2P 5C5
Calgary, AB, CA
Calgary, AB, CA
CEO
Constantine Nkafu
Website
cannapharmarx.com
IPO
1999-10-29
CIK 1081938 ISIN US13765D1090
Description
CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis. Founded in 1998, its main offices are located in Calgary, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
167.7K
Beta
0.51
Float Shares
631.33M
Free Float %
93.0%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-28.92
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+66.1% ★ Q1'26: +87.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-26.6% Q1'26: +40.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-785.5% Q1'26: -38.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-637.4% Q1'26: -108.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +29.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.0% Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.38× Q1'26: -7.68× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.06M
OE per share TTM
0.00
Owner's Yield
72.14%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,170.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Andrew I. Telsey | 933.6K | 19.80% | — | — | — | — | IN | U.S. | 2000-02-14 | ↗ |
| 2 | Boutine Capital, LLC | 539.0K | 10.90% | — | — | — | — | OO | CO | 2001-02-12 | ↗ |
| 3 | David J. Selina | 432.5K | 8.20% | — | — | — | — | IN | U.S. | 2001-02-06 | ↗ |
| 4 | Craig E. Lassen | 307.6K | 6.50% | — | — | — | — | IN | U.S. | 2000-06-19 | ↗ |
| 5 | Jeffrey W. Marshall | 298.9K | 5.80% | — | — | — | 500.00 | IN | U.S. | 2001-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
1.00M
Cash buys
—
Cash sales
1.00
Net activity
-1,000,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | Zemel Elliot | Director | — | — | Common shares | 0 | 0.00 | — | 23,368,212 | I | ↗ |
| 2025-03-31 | Tal Amir David | Director | — | — | Common Stock | 0 | 0.00 | — | 23,368,212 | D | ↗ |
| 2023-08-15 | Panek Anthony Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-10-08 | Colvin Dominic | Director / Officer | S-Sale | D | Common Stock | 1,000,000 | 0.25 | 250.0K | 6,988,963 | — | ↗ |
| 2019-06-17 | Nicosia Matthew | Director / 10% Owner | S-Sale | D | Series A Preferred | 4,000 | 0.00 | — | 16,000 | — | ↗ |
| 2019-04-23 | Steedman Andrew Clifford | Officer | — | D | Series A Convertible Preferred Stock | 0 | 0.00 | — | 4,000 | — | ↗ |
| 2019-04-23 | SAMUELSON JAMES F | Director / 10% Owner | S-Sale | D | Series A Convertible Preferred Stock | 1,200 | 0.00 | — | 14,800 | — | ↗ |
| 2019-04-23 | Orman Richard Dale | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-23 | Cassels John Hamilton | Officer | — | D | Series A Convertible Preferred Stock | 5,000,000 | 0.00 | — | 0 | — | ↗ |
| 2019-04-23 | BRANSON MARC R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-26 | Colvin Dominic | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 7,988,963 | — | ↗ |
| 2019-01-02 | Herick Gary J | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 2.00 | 200.0K | 600,000 | — | ↗ |
| 2018-06-27 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 40,000 | 0.50 | 20.0K | 0 | — | ↗ |
| 2018-04-23 | SAMUELSON JAMES F | Director / 10% Owner | S-Sale | D | Series A Convertible Preferred Stock | 4,000 | 0.00 | — | 16,000 | — | ↗ |
| 2018-04-20 | SAMUELSON JAMES F | Director / 10% Owner | J-Other | A | Convertible Preferred Stock | 10,000 | 0.00 | — | 31,000,000 | — | ↗ |
| 2018-04-20 | Nicosia Matthew | Director / 10% Owner | J-Other | D | Series A Preferred | 10,000 | 0.00 | — | 26,000 | — | ↗ |
| 2018-04-20 | Herick Gary J | Director / Officer | A-Award | A | Series A Convertible Preferred Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2015-12-15 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 30,000 | 1.00 | 30.0K | 226,000 | — | ↗ |
| 2015-12-14 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 35,000 | 1.00 | 35.0K | 202,000 | — | ↗ |
| 2015-11-01 | SMEEDING JAMES E | Director | — | D | Stock Options | 750,000 | 1.00 | 750.0K | 0 | — | ↗ |
| 2015-11-01 | SHERWOOD MATHEW D | Director | — | D | Stock Options | 750,000 | 1.00 | 750.0K | 0 | — | ↗ |
| 2015-08-11 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.00 | 25.0K | 471,000 | — | ↗ |
| 2015-07-31 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 3,000 | 1.00 | 3.0K | 537,000 | — | ↗ |
| 2015-07-27 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 10,000 | 1.00 | 10.0K | 540,000 | — | ↗ |
| 2015-07-10 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 50,000 | 1.00 | 50.0K | 550,000 | — | ↗ |
| 2015-06-29 | SMEEDING JAMES E | Director | — | D | Common Stock | 0 | 0.00 | — | 1,250,000 | — | ↗ |
| 2015-06-29 | SHERWOOD MATHEW D | Director | — | D | Common Stock | 0 | 0.00 | — | 1,130,000 | — | ↗ |
| 2015-06-29 | LIESS ROBERT M | Director | — | D | Common Stock | 0 | 0.00 | — | 800,000 | — | ↗ |
| 2015-06-29 | Herick Gary J | Director | J-Other | A | Common Stock | 400,000 | 0.00 | 40.00 | 400,000 | — | ↗ |
| 2015-06-29 | CannaPharmaRX, Inc. | — | J-Other | D | Common Stock | 10,421,120 | 0.00 | — | 0 | — | ↗ |
| 2015-06-29 | CROCKER GERALD EUGENE JR | Director / Officer | J-Other | A | Common Stock | 60,000 | 0.00 | 6.00 | 60,000 | — | ↗ |
| 2015-05-11 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.00 | 25.0K | 250,000 | — | ↗ |
| 2015-05-03 | Herick Gary J | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 600,000 | — | ↗ |
| 2015-04-14 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 125,000 | 0.00 | — | 275,000 | — | ↗ |
| 2015-04-01 | RULE STEVEN J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-04-01 | KHALIFE ELIE M | Director | — | I | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2015-04-01 | Giaquinto Alexander R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-03-09 | Herick Gary J | Director / Officer | S-Sale | D | Common Stock | 50,000 | 1.00 | 50.0K | 860,000 | — | ↗ |
| 2015-02-27 | POHL DAVID R | Director | — | D | Common Stock | 0 | 0.00 | — | 300,000 | — | ↗ |
| 2015-02-27 | DICICCO WENDY F | Director | A-Award | A | OPTION | 50,000 | 2.60 | 130.0K | 50,000 | — | ↗ |
| 2015-02-09 | SCHNITTKER CHRISTOPHER P. | Officer | A-Award | A | STOCK OPTION | 450,000 | 2.50 | 1.13M | 450,000 | — | ↗ |
| 2014-11-01 | Herick Gary J | Director | A-Award | A | Stock Options | 750,000 | 1.00 | 750.0K | 750,000 | — | ↗ |
| 2014-11-01 | CROCKER GERALD EUGENE JR | Director / Officer | A-Award | A | Stock Options | 750,000 | 1.00 | 750.0K | 750,000 | — | ↗ |
| 2014-05-09 | Herick Gary J | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,421,120 | — | ↗ |
| 2014-05-09 | Green Redgie T | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 125,000 | — | ↗ |
| 2014-05-09 | Cutler David J | Director | J-Other | D | Common Stock | 1,421,120 | 0.04 | 53.9K | 0 | — | ↗ |
| 2014-05-09 | CannaPharmaRX, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,421,120 | — | ↗ |
| 2014-05-09 | CROCKER GERALD EUGENE JR | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,421,120 | — | ↗ |
| 2014-05-09 | COHEN GARY MICHAEL | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,421,120 | — | ↗ |
| 2008-08-22 | Cutler David J | Director | A-Award | A | Common Stock | 26,421 | 1.00 | 26.4K | 1,521,120 | — | ↗ |
| 2007-12-03 | CUTLER DAVID J | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 87,055 | 1.00 | 87.1K | 1,494,699 | — | ↗ |
| 2006-03-07 | WHITING WESLEY F | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2006-03-07 | Green Redgie T | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2005-04-22 | CUTLER DAVID J | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,407,644 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-3.3K
Shares Outstanding
678.50M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019 | Dominic Colvin, CEO | 64.0K | — | — | — | — | — | 64.0K | 0.00% | ↗ |
| 2 | 2019 | Gary Herick, CFO, Secretary Jim Samuelson | 56.5K | — | — | — | — | — | 56.5K | 0.00% | ↗ |
| 3 | 2018 | Gary Herick, CFO, Secretary | 199.3K | — | — | — | — | — | 199.3K | 0.00% | ↗ |
| 4 | 2018 | Gary Herick, CFO, Secretary Jim Samuelson | 199.3K | — | — | — | — | — | 199.3K | 0.00% | ↗ |
| 5 | 2018 | Nick Colvin | 27.5K | — | — | — | — | — | 27.5K | 0.00% | ↗ |
| 6 | 2018 | James Samuelson | 27.5K | — | — | — | — | — | 27.5K | 0.00% | ↗ |
| 7 | 2018 | Dominic Colvin, CEO | 27.5K | — | — | — | — | — | 27.5K | 0.00% | ↗ |
| 8 | 2018 | Matthew Nicosia James Smeeding, President Mathew Sherwood, VP of RD | 27.5K | — | — | — | — | — | 27.5K | 0.00% | ↗ |
| 9 | 2017 | Gary Herick, CFO, Secretary | — | — | — | — | — | — | — | — | ↗ |
| 10 | 2016 | Gary Herick, CFO, Secretary | 92.5K | — | — | — | — | — | 92.5K | 0.00% | ↗ |
| 11 | 2016 | Matthew Nicosia James Smeeding, President Mathew Sherwood, VP of RD | 50.0K | — | — | — | — | — | 50.0K | 0.00% | ↗ |
| 12 | 2014 | Gary Herick, CFO, Secretary Jim Samuelson | 25.0K | 55.0K | — | — | — | 76.5K | 2.33M | 0.00% | ↗ |
| 13 | 2014 | Gerald E. Crocker, | 25.0K | — | — | — | — | 51.6K | 2.25M | 0.00% | ↗ |
| 14 | 2014 | David J. Cutler, former Chief Executive Officer and Chief Financial Officer | 15.0K | — | — | — | — | — | 15.0K | 0.00% | ↗ |
| 15 | 2013 | David J. Cutler, former Chief Executive Officer and Chief Financial Officer | 60.0K | — | — | — | — | — | 60.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Oliver W. Foeste | Chief Financial Officer | 203.7K | male |
| Constantine Nkafu | CEO & Director | 122.5K | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CPMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
